<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725994</url>
  </required_header>
  <id_info>
    <org_study_id>ID-VDP-103</org_study_id>
    <nct_id>NCT04725994</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>An Open-Label, International, Multicenter, Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1b study to evaluate the safety and tolerability of IDX-1197 and&#xD;
      determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced&#xD;
      gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>through study completion (Up to 12 months)</time_frame>
    <description>To determine the MTD and RP2D of IDX-1197 when given in combination with XELOX or Irinotecan. This will be accomplished by the standard 3+3 dose escalation design. If 2 of the 3 to 6 patients in a particular dose level experience a DLT, the dose escalation should be stopped at this dose level, and the MTD will be determined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>during the first 21-day cycle for Group 1 and through first 2 cycles (14 days each) for Group 2</time_frame>
    <description>Occurrence of DLTs</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX-1197+XELOX</intervention_name>
    <description>The dose levels will be escalated following a 3+3 dose escalation scheme.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX-1197+Irinotecan</intervention_name>
    <description>The dose levels will be escalated following a 3+3 dose escalation scheme.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group 1, patients with treatment-naïve recurrent or advanced metastatic gastric cancer&#xD;
             including gastroesophageal junction or upper part of the stomach.&#xD;
&#xD;
          -  Group 2, patients with recurrent or advanced metastatic gastric cancer including&#xD;
             gastroesophageal junction or upper part of the stomach, who were treated ≥2 times with&#xD;
             palliative chemotherapy before screening.&#xD;
&#xD;
          -  At least 1 evaluable lesion for the dose escalation part and at least 1 measurable&#xD;
             lesion according to RECIST v1.1 for the dose expansion part.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic central nervous system or uncontrolled brain metastasis&#xD;
&#xD;
          -  Carcinomatous meningitis or its history.&#xD;
&#xD;
          -  For Group 1, patients who are HER 2 positive.&#xD;
&#xD;
          -  Any other concurrent uncontrolled illness including, but not limited to, active or&#xD;
             ongoing symptomatic infection requiring IV antibiotic treatment, uncontrolled&#xD;
             diabetes, hepatic, renal, or respiratory illness.&#xD;
&#xD;
          -  Severe or unstable angina, myocardial infarction or ischemia, symptomatic congestive&#xD;
             heart failure, arterial or venous thromboembolism requiring coronary artery bypass&#xD;
             graft or stent within the past 6 months or clinically significant cardiac dysrhythmia&#xD;
             or New York Heart Association class II ~ IV heart disease within 6 months of&#xD;
             randomization.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Immunocompromised patients, such as patients known to be serologically positive for&#xD;
             HIV.&#xD;
&#xD;
          -  Patients with known active Hepatitis B or C infection.&#xD;
&#xD;
          -  Patients with known active or symptomatic pneumonitis, or history of non-infectious&#xD;
             pneumonitis requiring steroids.&#xD;
&#xD;
          -  Diagnosis of a myelodysplastic syndrome/acute myeloid leukemia or its suspicious&#xD;
             characteristics.&#xD;
&#xD;
          -  Any unresolved clinically significant Common Terminology Criteria for Adverse Events&#xD;
             (CTCAE) Grade ≥2 toxicity&#xD;
&#xD;
          -  Resting ECG with measurable QTcF &gt; 470 msec on 2 or more time points within a 24-hour&#xD;
             period or family history of long QT syndrome.&#xD;
&#xD;
          -  Current use of a cytochrome P3A4 inhibitor or inducer and strong uridine diphosphate&#xD;
             (UDP)-glucuronosyltransferase 1A1 (UGT1A1) inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Won Sik Lee</last_name>
    <phone>82-2-526-3612</phone>
    <email>wonsiklee@idience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Minju Hong</last_name>
    <phone>82-2-526-3644</phone>
    <email>minju.hong@idience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC Norris Comp. Cancer Ctr Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital - Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

